Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.

[1]  M. Ng,et al.  Frequent hypermethylation of p16 and p15 genes in multiple myeloma. , 1997, Blood.

[2]  J. Benítez,et al.  Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin’s lymphoma , 1997, Leukemia.

[3]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[4]  J. Geradts,et al.  High frequency of aberrant p16(INK4A) expression in human breast cancer. , 1996, The American journal of pathology.

[5]  C. Cordon-Cardo,et al.  Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. , 1996, The American journal of pathology.

[6]  F. Sigaux,et al.  Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. , 1996, Blood.

[7]  F. Kaye,et al.  Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. , 1995, Journal of the National Cancer Institute.

[8]  R. Kratzke,et al.  Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.

[9]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[10]  R. Siebert,et al.  Homozygous loss of the MTSl/pl6 and MTS2/pl5 genes in lymphoma and lymphoblastic leukaemia cell lines , 1995, British journal of haematology.

[11]  T. Kinoshita,et al.  Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. , 1995, Blood.

[12]  O. Olopade,et al.  Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. , 1995, Blood.

[13]  S. Ogawa,et al.  Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. , 1995, Blood.

[14]  H. Koeffler,et al.  Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. , 1995, Blood.

[15]  Y. Hayashi,et al.  Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. , 1995, Blood.

[16]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[17]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[18]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[19]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[20]  W Arap,et al.  Loss of P16INK4 expression is frequent in high grade gliomas. , 1995, Cancer research.

[21]  M. Piris,et al.  Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Yuille,et al.  Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.

[23]  R. Ueda,et al.  In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. , 1995, Cancer research.

[24]  R. DePinho,et al.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.

[25]  G. Finocchiaro,et al.  Mutation rate of the CDKN2 gene in malignant gliomas. , 1994, Cancer research.

[26]  M. Pagano,et al.  Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. , 1994, Cancer research.

[27]  I. Herskowitz,et al.  Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle , 1994, Cell.

[28]  K. Tanaka,et al.  Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. , 1994, Blood.

[29]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[30]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[31]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[32]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[33]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[34]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[35]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[36]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[38]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[39]  Y. Xiong,et al.  Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. , 1995, Blood.

[40]  G. Hannon,et al.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. , 1994, Nature.

[41]  M. Borrello,et al.  Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. , 1992, Cytometry.